Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

被引：24

作者：

Faivre-Finn, C. ^{[1
,2
]}

Vicente, D. ^{[3
]}

Kurata, T. ^{[4
]}

Planchard, D. ^{[5
]}

Paz-Ares, L. ^{[6
,7
]}

Vansteenkiste, J. F. ^{[8
]}

Spigel, D. R. ^{[9
,10
]}

Garassino, M. C. ^{[11
]}

Reck, M. ^{[12
]}

Senan, S. ^{[13
]}

Naidoo, J. ^{[14
,15
,16
]}

Rimner, A. ^{[16
]}

Wu, Y-L. ^{[17
,18
]}

Gray, J. E. ^{[19
]}

Ozguroglu, M. ^{[20
]}

Lee, K. H. ^{[21
]}

Newton, M. ^{[22
]}

Wang, L. ^{[22
]}

Thiyagarajah, P. ^{[23
]}

Antonia, S. J. ^{[19
]}

机构：

[1] Univ Manchester, Manchester, Lancs, England

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] Hosp Univ Virgen Macarena, Seville, Spain

[4] Kansai Med Univ Hosp, Hirakata, Osaka, Japan

[5] Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France

[6] Univ Complutense, Hosp Univ 12 Octubre, CiberOnc, Madrid, Spain

[7] CNIO, Madrid, Spain

[8] Univ Hosp KU Leuven, Dept Resp Oncol, Leuven, Belgium

[9] Sarah Cannon Res Inst, Nashville, TN USA

[10] Tennessee Oncol, Nashville, TN USA

[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[12] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany

[13] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands

[14] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[15] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA

[16] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA

[17] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Dept Pulm Oncol, Guangzhou, Peoples R China

[18] Guangdong Acad Med Sci, Guangzhou, Peoples R China

[19] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[20] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey

[21] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[22] AstraZeneca, Gaithersburg, MD USA

[23] AstraZeneca, Cambridge, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2281

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA49

引用

页码：S1178 / S1179

页数：2

共 50 条

[41] Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Garassino, M. C.
Mazieres, J.
Reck, M.
Chouaid, C.
Bischoff, H.
Reinmuth, N.
Cove-Smith, L. S.
Mansy, T.
Cortinovis, D. L.
Migliorino, M. R.
Delmonte, A.
Sanchez, J. Garcia
Velarde, L. E. Chara
Caro, R. Bernabe
Paz-Ares, L.
Chander, P.
Perez, I. Diaz
Foroutanpour, K.
Faivre-Finn, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1301 - S1302
[42] Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Naidoo, Jarushka
Antonia, Scott
Wu, Yi-Long
Cho, Byoung Chul
Thiyagarajah, Piruntha
Mann, Helen
Newton, Michael
Faivre-Finn, Corinne
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 657 - 663
[43] Safety and Efficacy Results of Durvalumab following Sequential Chemoradiotherapy (sCRT) in Unresectable Stage III NSCLC (PACIFIC 6)
Heilmann, M.
Garassino, M. C.
Mazieres, J.
Chouaid, C.
Bischoff, H.
Reinmuth, N.
Cove-Smith, L.
Mansy, T.
Cortinovis, D.
Migliorino, M. R.
Delmonte, A.
Sanchez, J. G.
Velarde, L. E. C.
Bernabe, R.
Paz-Ares, L.
Perez, Diaz, I
Trunova, N.
Foroutanpour, K.
Faivre-Finn, C.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 97 - 98
[44] Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy
Taugner, Julian
Kaesmann, Lukas
Eze, Chukwuka
Dantes, Maurice
Roengvoraphoj, Olarn
Gennen, Kathrin
Karin, Monika
Petruknov, Oleg
Tufman, Amanda
Belka, Claus
Manapov, Farkhad
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 593 - 604
[45] PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum -based chemoradiotherapy in patients with unresectable, stage III NSCLC.
Bradley, Jeffrey D.
Nishio, Makoto
Okamoto, Isamu
Newton, Michael David
Trani, Leonardo
Shire, Norah J.
Gu, Yu
Dennis, Philip A.
Lee, Ki Hyeong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46] Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer (vol 40, pg 1301, 2022)
Spigel, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17) : 1965 - 1965
[47] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Park, Cheol-Kyu
Oh, Hyung-Joo
Kim, Young-Chul
Kim, Yong-Hyub
Ahn, Sung-Ja
Jeong, Won Gi
Lee, Jeong Yeop
Lee, Jae Cheol
Choi, Chang Min
Ji, Wonjun
Song, Si Yeol
Choi, Juwhan
Lee, Sung Yong
Kim, Hakyoung
Lee, Shin Yup
Park, Jongmoo
Yoon, Seong Hoon
Joo, Ji Hyeon
Oh, In-Jae
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054
[48] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
Girard, N.
Mornex, F.
Christoph, D. C.
Fietkau, R.
Filippi, A. R.
Field, J.
Garrido Lopez, P.
McDonald, F.
Peters, S.
Klein, A. B.
Licour, M.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30
[49] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
Christoph, D. C.
Behringer, D.
Emde, T. O.
Goekkurt, E.
Laack, E.
Mueller-Huesmann, H.
Schuett, P.
Schumann, C.
Seese, B.
Fietkau, R.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
[50] First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
Planchard, David
Cho, Byoung Chul
Gray, Jhanelle Elaine
Paz-Ares, Luis G.
Ozguroglu, Mustafa
Villegas, Augusto E.
Daniel, Davey B.
Vicente, David
Murakami, Shuji
Hui, Rina
Kurata, Takayasu
Chiappori, Alberto
Lee, Ki Hyeong
De Wit, Maike
Gu, Yu
Wadsworth, Catherine
Dennis, Phillip A.
Antonia, Scott Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →